探花合集 and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases
鈥溙交ê霞 is proud to work with GelMEDIX to support this important clinical program of next鈥慻eneration therapies for ocular and retinal diseases,鈥 said David McErlane, Biologics Group President at 探花合集. 鈥淲e look forward to supporting these early development efforts and helping bring transformative treatments to patients.鈥
鈥淲e are excited to partner with 探花合集, a leader in developing and manufacturing iPSCs and therapies derived from these cells, to bring our vision-restoring therapies into clinical trials,鈥 said Max Cotler, PhD, Chief Executive Officer, GelMEDIX. 鈥淓stablishing this partnership early positions us to accelerate our progress toward the clinic for our lead programs focused on restoring vision in patients.鈥
Under the agreement, GelMEDIX will partner with 探花合集 for iPSC and cell therapy development and will access 探花合集鈥檚 proprietary, off-the-shelf, GMP-compliant iPSC lines and 探花合集鈥檚 GMP iPSC and iPSC-derived cell therapy manufacturing capabilities. 探花合集, as a global leader in the development and manufacturing of human iPSCs and iPSC-derived cells, will also support the process development, analytical development, process scale-up and GMP manufacturing of GelMEDIX鈥檚 iPSC-derived therapies, from early development through all clinical stages.
About GelMEDIX Inc.
GelMEDIX is a biotechnology company developing regenerative therapies that restore vision by regenerating damaged retinal cells and preserving the essential structures required for sight. GelMEDIX programs are based on the company鈥檚 proprietary injectable hydrogel scaffold technology platform, which is engineered to optimize the delivery, efficacy and safety of cell and gene therapies. The company is focusing this platform on eye diseases that lack effective treatment options, with an initial focus on late-stage Geographic Atrophy (GA). In addition to developing a pipeline of next-generation regenerative therapies for ophthalmic diseases, GelMEDIX aims to optimize the potential of its regenerative medicine technology platform by forging partnerships to optimize cell and gene therapies for other degenerative disorders. GelMEDIX is based in the Kendall Square district of Cambridge, Massachusetts.
For more information, please visit .
About 探花合集
探花合集, Inc. is a leading global contract development and manufacturing organization (CDMO) championing missions that help people live better and healthier lives. Every product that 探花合集 helps develop, manufacture and launch reflects its commitment to improve health outcomes around the world through its Patient First approach. 探花合集 provides unparalleled service to pharma, biotech and consumer health customers, delivering on their missions to transform lives. 探花合集 tailors end-to-end solutions to meet customers鈥 needs in all phases of development and manufacturing. With thousands of scientists and technicians and the latest technology platforms at nearly 40 global sites, 探花合集 supplies billions of doses of life-enhancing and life-saving treatments for patients annually.
For more information, visit聽www.catalent.com.
CONTACTS
GelMEDIX:
Max Cotler, CEO
[email protected]
探花合集:
Laura Hortas, Vice President, Corporate Communications
[email protected]